Unlock GLP-1 Access: Your Guide to Patient Assistance Programs

A staggering 41.9% of U.S. adults experienced obesity in 2021–2022, a figure that continues its relentless climb according to the National Center for Health Statistics at the CDC. For many of these individuals, the advent of GLP-1 receptor agonists has offered a profound, evidence-backed pathway to significant weight loss and improved metabolic health, yet the prohibitive cost of these transformative medications remains a critical barrier.

Last Updated: June 2024

The sticker shock for GLP-1 drugs like Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Zepbound and Mounjaro, is not merely anecdotal; it is a systemic problem. Without insurance, monthly costs can soar past $1,000, rendering life-changing treatment inaccessible for most Americans. Even with insurance, high deductibles, co-pays, and outright non-coverage for weight loss indications frequently push these drugs out of reach. This financial chasm has made manufacturer-sponsored patient assistance programs (PAPs) a vital, albeit bureaucratic, lifeline.

These programs, typically managed by the pharmaceutical companies themselves, are designed to provide free or low-cost medications to eligible patients who are uninsured or underinsured and meet specific income criteria. While they serve a crucial function in bridging gaps created by a convoluted healthcare payment system, their very existence highlights a troubling reality: patients are forced to navigate complex applications and prove financial hardship to access treatments that should be readily available based on medical necessity.

Novo Nordisk Patient Assistance Program (NNPAP)

Novo Nordisk, the manufacturer of popular GLP-1s such as Ozempic (semaglutide, for type 2 diabetes), Rybelsus (oral semaglutide, for type 2 diabetes), and Wegovy (semaglutide, for chronic weight management), operates a patient assistance program designed to help those facing financial hurdles. The program provides certain Novo Nordisk medications at no cost to eligible individuals. It is critical to note that Ozempic and Rybelsus are FDA-approved for type 2 diabetes, while Wegovy is specifically approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity.

Eligibility for NNPAP

• Income Requirements: Applicants must have a household income at or below 400% of the Federal Poverty Level (FPL). For instance, in 2024, 400% FPL for an individual is approximately $58,320, and for a household of four, it is around $120,000. These figures are subject to change annually based on FPL updates.
• Insurance Status: The program primarily assists U.S. citizens or legal residents who do not have private prescription drug coverage, or who have Medicare Part D and meet specific income requirements. Patients with commercial insurance that covers the medication are generally not eligible. Importantly, individuals covered by Medicaid, Tricare, or VA benefits are also typically excluded as these programs have their own drug coverage mechanisms.
• Residency: Applicants must be U.S. citizens or legal residents living in the U.S.
• Prescription: A valid prescription for a Novo Nordisk medication from a licensed U.S. healthcare provider is mandatory.

How to Apply for NNPAP

The application process for the Novo Nordisk Patient Assistance Program typically involves several steps:

1. Obtain Application Form: The form can be downloaded from the Novo Nordisk website or obtained through your healthcare provider's office.
2. Healthcare Provider Section: Your prescribing physician must complete a section of the application, verifying your medical necessity for the drug and providing their license information. This often requires the doctor's office to submit the application on your behalf.
3. Patient Section: You, the patient, will need to complete your personal and financial information, including household income, proof of residency, and details about your insurance coverage. Required documents often include tax returns, W-2 forms, or other income verification.
4. Submission: The completed application, along with all supporting documentation, is typically faxed or mailed to the NNPAP.
5. Review and Notification: Novo Nordisk reviews applications, a process that can take several weeks. You will be notified of the decision via mail. If approved, the medication will be shipped directly to your healthcare provider's office or a designated pharmacy for pick-up.

Lilly Cares Foundation Patient Assistance Program

Eli Lilly, the maker of Mounjaro (tirzepatide, for type 2 diabetes) and Zepbound (tirzepatide, for chronic weight management), operates the Lilly Cares Foundation. This independent non-profit organization provides free Lilly medicines to U.S. patients who meet specific eligibility criteria. Like Novo Nordisk, Lilly's GLP-1s represent significant advancements, with Mounjaro and Zepbound showing impressive efficacy in both glycemic control and weight reduction. The Lilly Cares program aims to ensure these innovations reach patients regardless of their ability to pay the often-